Rigel Announces Conference Call and Webcast to Report Second Quarter 2020 Financial Results and Business Update

Rhea-AI Summary

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) will disclose its second quarter 2020 financial results on August 4, 2020, after market close. Following the announcement, a live conference call will be held at 4:30pm ET to discuss the results and business updates. Interested participants can join by dialing (877) 407-3088 (domestic) or (201) 389-0927 (international). Rigel focuses on developing innovative small molecule drugs for immune and hematologic disorders. Their lead product, TAVALISSE, is approved for chronic immune thrombocytopenia.

Positive

• Rigel's ongoing clinical trials and partnerships may lead to potential drug developments.
• The FDA-approved product TAVALISSE addresses a significant market need for chronic immune thrombocytopenia.

Negative

• No specific financial metrics or guidance were provided in the PR.

SOUTH SAN FRANCISCO, Calif., July 28, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2020 financial results after market close on Tuesday, August 4, 2020.  Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial results and give an update on the business.

Participants can access the live conference call by dialing (877) 407-3088 (domestic) or (201) 389-0927 (international).  The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website at www.rigel.com.  The webcast will be archived and available for replay for 90 days after the call via the Rigel website.

About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE^® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product has been approved by the European Commission for the treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments and is marketed in Europe under the name TAVLESSE^® (fostamatinib). Fostamatinib is currently being studied in an investigator-sponsored trial conducted by Imperial College London for the treatment of COVID-19 pneumonia¹.

Rigel's clinical programs include a Phase 3 study of fostamatinib in warm autoimmune hemolytic anemia (AIHA); a completed Phase 1 study of R835¹, a proprietary molecule from its interleukin receptor associated kinase (IRAK) inhibitor program; and an ongoing Phase 1 study of R552¹, a proprietary molecule from its receptor-interacting protein kinase (RIP) inhibitor program. In addition, Rigel has product candidates in clinical development with partners Aclaris Therapeutics, AstraZeneca, BerGenBio ASA, and Daiichi Sankyo.

Please see www.TAVALISSE.com for the full Prescribing Information.

¹The product for this use or indication is investigational and has not been proven safe or effective by any regulatory authority.

Contact: David Burke
Phone: 650.624.1232
Email: dburke@rigel.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2020-financial-results-and-business-update-301100724.html

SOURCE Rigel Pharmaceuticals, Inc.

FAQ

What date will Rigel report its second quarter 2020 financial results?

Rigel will report its second quarter 2020 financial results on August 4, 2020.

What time is the Rigel conference call for second quarter results?

The conference call will take place at 4:30pm Eastern Time.

How can I access Rigel's conference call on August 4, 2020?

You can access the conference call by dialing (877) 407-3088 domestically or (201) 389-0927 internationally.

What is Rigel's main product and its indication?

Rigel's main product is TAVALISSE, indicated for adult patients with chronic immune thrombocytopenia.

Where can I find the live webcast of the Rigel conference call?

The live webcast can be accessed in the Investor Relations section of Rigel's website.